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Disruption of the leptomeningeal blood
barrier in neuromyelitis optica spectrum
disorder
ABSTRACT
Objective: To describe leptomeningeal blood-barrier impairment reflected by MRI gadolinium-
enhanced lesions in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)–positive neuro-
myelitis optica spectrum disorder (NMOSD).
Methods: A retrospective case series of 11 AQP4-IgG–positive NMOSD patients with lep-
tomeningeal enhancement (LME) were collected from 5 centers. External neuroradiologists,
blinded to the clinical details, evaluated MRIs.
Results: LMEwas demonstrated on postcontrast T1-weighted and fluid-attenuated inversion recovery
images as a sign of leptomeningeal blood-barrier disruption and transient leakage of contrast agent into
the subarachnoid space in 11patients, 6 in the brain and6 in the spinal cord. The patterns of LMEwere
linear or extensive and were accompanied by periependymal enhancement in 5 cases and intraparen-
chymal enhancement in all cases. The location of LME in the spinal cordwas adjacent to intraparenchy-
mal contrast enhancement with involvement of a median number of 12 (range 5–17) vertebral
segments. At the time of LME on MRI, all patients had a clinical attack such as encephalopathy
(36%) and/or myelopathy (70%) with median interval between symptom onset and LME of 12 days
(range2–30). LMEoccurred in associationwith an initial area postrema attack (44%), signs of systemic
infection (33%), or AQP4-IgG in CSF (22%) followed by clinical progression. LME was found at initial
clinical presentation in 5 cases and at clinical relapses leading to a diagnosis of NMOSD in 6 cases.
Conclusion: This study suggests that altered leptomeningeal blood barrier may be accompanied by
intraparenchymal blood-brain barrier breakdown in patients with AQP4-IgG–positive NMOSDduring
relapses. Neurol Neuroimmunol Neuroinflamm 2017;4:e343; doi: 10.1212/NXI.0000000000000343
GLOSSARY
AP 5 area postrema syndrome/lesion; AQP4 5 aquaporin-4; BBB 5 blood-brain barrier; CS 5 cerebral syndromes; DWI 5
diffusion-weighted imaging; FLAIR 5 fluid-attenuated inversion recovery; Gd 5 gadolinium; IVMP 5 IV methylprednisolone;
LETM 5 longitudinally extensive transverse myelitis; LME 5 leptomeningeal enhancement; MNL 5 mononuclear leukocyte;
NMOSD 5 neuromyelitis optica spectrum disorder; ON 5 optic neuritis; PLEX 5 plasma exchange; PMNL 5 polymorphonu-
clear leukocyte; STIR 5 short tau inversion recovery; T1W 5 T1 weighted.
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory, autoimmune disease of
the CNS that follows a relapsing course in the majority of patients. NMOSD-related neurologic
disability frequently occurs as a consequence of cumulative attacks.1 The inflammation of
NMOSD is often associated with blood-brain barrier (BBB) leakage, reflected by MRI
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gadolinium (Gd)-enhanced lesions.2–4 Serum-
derived aquaporin-4 immunoglobulin G
(AQP4-IgG) antibody is believed to play an
important and potentially pivotal role in
NMOSD pathogenesis1; however, the mecha-
nism whereby AQP4-IgG contributes to BBB
leakage remains poorly characterized. The
autoantigen AQP4 is densely localized on
ependymal cells and astrocyte end-feet, form-
ing the glia limitans of the BBB.5 The lack of
a basement membrane and expression of tight
junctions in ependymal cells may allow
AQP4-IgG in the CSF to get access to its
target.5–7 AQP4-IgG may exert pathologic ef-
fects by binding selectively to AQP4 on CNS
astrocytes, inducing complement-dependent
astrocyte damage and inflammation.8
MRI-detected leptomeningeal enhance-
ment (LME), which reflects the leptomenin-
geal blood-barrier disruption, has been
reported in patients with NMOSD.2 LME re-
fers to an enhancement pattern that follows
the pial surface of the CNS and fills the sub-
arachnoid spaces of sulci and cisterns. The
LME pattern depends on the extent and inten-
sity of the involved inflammatory area and
may provide useful clues to the diagnosis of,
e.g., neurosarcoidosis.9
In this retrospective case study, we investi-
gated whether compromised integrity of the
intraparenchymal BBB occurs concurrently
with LME and whether such an alteration of
BBB is associated with disease activity in pa-
tients with AQP4-IgG–positive NMOSD.
METHODS Study design and population. The study was
designed as a retrospective case series with clinical and radiologic
follow-up and collected by a multicenter study group in 5 centers
(Japan, South Korea, United States, France, and Denmark). Pa-
tients were included if they met the following criteria: (1) AQP4-
IgG–positive NMOSD, qualifying for the 2006 Wingerchuk
criteria10 or/and the International Panel for NMO Diagnosis
(IPND) 201511 and (2) LME as visualized by MRI following the
standard protocols.12,13 Patients were excluded if they had (1)
systemic inflammatory disease, e.g., sarcoidosis or (2) neoplastic
disease. The information was obtained by review of medical re-
cords and reevaluation of previous MRIs of the CNS by local
neuroradiologists. In addition, 2 expert neuroradiologists not
involved in patient management evaluated images and were
blinded to the clinical details (H.P.S. and J.W.).
Neuroimaging. Because the study was retrospective, several
types of 1.5T MRI scanners were used. T2-weighted (T2W)
and T1-weighted (T1W) images with or without Gd, diffusion-
weighted imaging, and fluid-attenuated inversion recovery
(FLAIR) sequences were available for analysis for all brain scans.
T2W and T1W with or without Gd and short tau inversion
recovery (STIR) sequences were available for spinal cord images.
Precontrast and postcontrast images were evaluated to determine
the presence of abnormal contrast enhancement on T1W and/or
FLAIR sequences according to the criteria previously reported.12–14 If
performed, postcontrast FLAIR sequences obtained at least
10 minutes after a single dose of contrast were also used for
evaluation.
Standard protocol approvals, registrations, and patient
consents. All patients provided oral and written informed con-
sent for publication.
RESULTS Retrospective MRI and clinical data from
11 AQP4-IgG–positive (measured either in a cell-
based assay or ELISA15) NMOSD patients with lep-
tomeningeal enhancement (LME) were obtained for
review (table 1). The female: male ratio was 9:2, and
the median age at onset of disease was 40.8 years (range
15–71 years). Seven patients were East Asian, 1 African
American, 1 of mixed ancestry, and 2 whites.
Radiologic characteristics. LME localization. Contrast
enhancement in the leptomeningeal space was evalu-
ated by precontrast and postcontrast T1W and/or
FLAIR images and observed in all 11 patients, 6 in
the brain and 6 in the spinal cord; 1 patient had both
brain and spinal cord LME.
In the brain, T1W contrast-enhanced images re-
vealed a linear or thick and extensive leptomeningeal
and pial enhancement with localization in both cere-
bral hemispheres (2 patients), bilateral medial surfaces
of the cerebral hemispheres (1), bilateral frontal,
medial parietal lobe (1), right parietal lobe (1), and
bilateral parieto-occipital lobes (1) (figure 1, A.a and b,
C.a and b). FLAIR (figure 1, A.c, B.c, C.c) and
FLAIR postcontrast (figure 1B.a) sequences revealed
similar leptomeningeal signal intensity changes.
In the spinal cord, T1W contrast-enhanced im-
ages showed LME in 6 patients, conus to cauda equi-
na (2), multifocal spinal cord (1), and thoracic
segments (3) (figure 2, A.a and c, B.a and C, figure
3B, figure 4, A and D, figure e-1, H1 and H3 at
Neurology.org/nn).
Follow-up MRI demonstrated resolution of LME
within 1–4 weeks in 9 patients. In one other case, the
next MRI was performed after 72 days when the
LME had disappeared. One patient did not have a
follow-up MRI.
LME in association with parenchymal enhancement.
LME in all cases spatially corresponded to intraparen-
chymal T1W contrast enhancement or/and FLAIR
image abnormalities in the brain (figure 1, A.c, B.c,
C.b and c). Periependymal linear T1W contrast
enhancement was localized at the lateral ventricles (3
patients) (figure 1B.b, figure 3D) and adjacent to the
third and fourth ventricles (2) (figure 3F). Intracerebral
cloud-like enhancement (3 patients) (figure 1C.c),
enhancement of hypothalamus (2) (figure 3G), and optic
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chiasm (1) were observed on T1W contrast-enhanced
or/and FLAIR sequences. In addition, parenchymal le-
sions were observed on T2W or/and FLAIR sequences
(figure 1, A.c, B.c, C.c, figure 3, A and E).
Spinal cord MRI demonstrated intraparenchymal
T1W contrast enhancement in the underlying paren-
chyma adjacent to the LME (figure 2, A.a and B.a,
figure 3B, figure 4B, figure e-1H1), involving cervi-
cal, thoracic, and lumbar cords. Spinal cord lesions
expanded over a median of 12 segments (range 5–17)
as demonstrated on contrast-enhanced T1W (figure
2, A.a and B.a, figure 3B, figure 4B, figure e-1H1)
and T2W and STIR images (figure 2, A.b and d, B.
b and d, figure 3, A and C, figure 4, C and E, figure
e-1, H2 and H4).
CSF abnormalities. Lumbar puncture was performed
after MRI investigation in all patients, and complete
CSF analysis was available at the time of the LME for
6 of the 11 patients. CSF examination showed pleo-
cytosis .50 mL (/mm3) in all cases; 2 cases with
increased polymorphonuclear leukocytes (PMNLs)
had 80% (PMNL 166 and mononuclear leukocyte
[MNL] 41/mm3) and 98% (PMNL 212 and MNL
4/mm3) PMNL, respectively. The combination of
LME and pleocytosis in all cases, especially in the 2
cases with increased CSF-PMNL and fever, led to
extensive virologic and bacteriologic workup, which
proved negative both in blood and CSF. The median
CSF protein concentration was 169 (range 54–322)
(mg/dL), and CSF glucose level was normal in all
cases. CSF-restricted oligoclonal bands or elevated
IgG CSF/serum ratio were absent, except in 1 patient.
AQP4-IgG in CSF was only measured in 2 patients,
and it was positive in both patients.
LME and clinical disease activity. When LME was vis-
ible on MRI, all patients had experienced attacks with
subacute onset and progressive neurologic deficits
over a few weeks (7 patients) or with acute onset
and rapid progression within a few days (4 patients).
Median interval between symptom onset and MRI
scans displaying LME was 12 days (range 2–30 days).
Seven patients had longitudinally extensive transverse
myelitis (LETM) (4 subacute and 3 acute onset) and
4 had cerebral syndromes (CS) (3 with subacute and
1 with acute onset) as the clinical presentation asso-
ciated with LME (table e-1).
Spinal cord involvement. In the LETM group, 3 of
the 4 patients with subacute onset initially had expe-
rienced an area postrema syndrome/lesion (episodes
of nausea, vomiting, and hiccups) (figure 3, A–C)
followed a few days later by extremity weakness,
which progressed to tetraplegia (1 patient) or para-
plegia (2) over 7, 12, and 30 days. MRI of the spinal
cord at this time revealed LETM with LME adjacent
to LETM. Another patient with a subacute onset of
LETM had atypical chest pain as the initial symptom,
which after 7 days progressed to paraplegia and MRI
of the spinal cord revealed LME and LETM (figure 4,
A–E).
Table 1 Clinical characteristics of the NMOSD patients with LME
Patient characteristics
NMOSD 1 AQP4-IgG 1 LME
(n 5 11)
Sex
F 9
M 2
Ethnicity
East Asian 7
African American 1
Mixed ancestry 1
White 2
Median age, y (range) 40.8 (15–71)
Median interval between symptom onset and
detection of LME on MRI, d (range)
12 (2–30)
Acute attack at the time of LME 11
Attack with LME as the initial clinical
presentation of NMOSD
5
Established NMOSD diagnosis at the time of
attack w/LME
6
LETM 4
CS 1 previous TM 1
LETM 1 previous ON 1
Clinical features at the time of LME on MRI
LETM 7
CS 4
AP 1 LETM 3
AP 1 CS 1
TM 1 CS 1
Median follow-up time after LME episode, mo
(range)
79 (2–186)
Disease course
Relapsing (F/M) 8 (88%/12%)
Monophasic (F/M) 3 (67%/33%)
Acute treatment IVMP (11) (additional PLEX in 7 patients
with LETM)
Preventive therapy after attack with LME
Oral corticosteroids 2
Azathioprine 2
Azathioprine 1 oral corticosteroids 1
Cyclosporine 1 oral corticosteroids 1
Mycophenolate mofetil 1
Mitoxantrone 2
Rituximab 2
Abbreviations: AP 5 area postrema syndrome/lesion; AQP4-IgG 5 aquaporin-4 immunoglob-
ulin G; CS 5 cerebral syndrome; IVMP 5 IV methylprednisolone; LETM 5 longitudinally exten-
sive transverse myelitis; LME5 leptomeningeal enhancement; NMOSD5 neuromyelitis optica
spectrum disorder; ON 5 optic neuritis; PLEX 5 plasma exchange; TM 5 transverse myelitis.
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In the remaining 3 patients with acute onset of
LETM, 2 developed symptom/signs after an upper
respiratory tract infection, by 2 and 4 days respec-
tively (without the identification of an infectious
agent) and 1 occurred 2 days after an induced abor-
tion. One presented with tetraplegia and 2 with para-
plegia. MRI of spinal cord revealed LETM with LME
adjacent to the intramedullary lesion (H1-H4).
Brain involvement. In the CS group, 1 patient ini-
tially experienced an area postrema syndrome fol-
lowed 10 days later by altered consciousness and
recurrent generalized seizures. Brain MRI performed
17 days after onset of symptoms revealed LME (figure
1, A.a–c). Another patient experienced dizziness and
was treated with corticosteroids. A third patient had
nonspecific symptoms such as drowsy mental state,
dysarthria, and recurrent episode of myelitis and optic
neuritis (ON). LME were in those 2 cases who dem-
onstrated on MRI 24 and 21 days after symptom
onset, respectively. The one patient with acute symp-
tom onset had a generalized seizure followed by tet-
raparesis from TM. LME was in this case
demonstrated on MRI 5 days after symptom onset
(table e-1).
Figure 1 Leptomeningeal enhancement accompanied by intraparenchymal enhancement during attacks in
patients with NMOSD
Contrast-enhanced cerebral T1W (A.a, A.b, B.b, C.a, and C.b), FLAIR sequences (A.c, B.a, B.c, and C.c) and FLAIR post–
contrast-enhanced image (B.a) MRI from 3 patients with AQP4-IgG–positive NMOSD (A, B, and C) during attacks, showing
leptomeningeal enhancement (A.a, A.b, B.a, C.a, and C.b), marked with arrows. Parenchymal lesions are seen including cloud-
like enhancement (B.c, A.c, and C.c). Notably, enhancement occurred at the ependymal surface of the lateral ventricles (B.a).
AQP4-IgG 5 aquaporin-4 immunoglobulin G; FLAIR 5 fluid-attenuated inversion recovery; NMOSD 5 neuromyelitis optica
spectrum disorder; T1W 5 T1 weighted.
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Acute and long-term immunotherapy. In all patients,
acute attacks were initially treated with IV methylpred-
nisolone (IVMP), which were administered between
the first and the follow-up MRI. The 7 patients with
LETM did not clinically respond to IVMP therapy
and were subsequently treated by plasma exchange.
Various immunosuppressive drugs as listed in
table 1 were used as preventive therapy after the
follow-up MRI, which showed resolution of LME;
one received azathioprine before the attack and
follow-up MRI examination.
LME and NMOSD diagnosis. LME was found at the
initial attack of NMOSD in 5 (3: LETM, 2: area
postrema syndrome) of the 11 patients (table 1). In
the remaining 6 patients, symptoms at first attack
were ON (2 patients), TM (1), AP (1), and CS (2).
A total of 6 patients, including all patients who
had LME at the initial attack, qualified for the diag-
nosis of NMOSD except one, with area postrema
syndrome, who received the NMOSD diagnosis 2
years later at testing for AQP4-IgG. Of the 6 patients,
2 had a history of TM and ON, respectively, and
received the diagnosis of NMOSD in association with
LME and acute attack, 1 with LETM, and 1 with
a generalized seizure followed by TM (table 1).
Three patients with previous attacks received the
NMOSD diagnosis at median 20 months (range
12–24) after attack with LME on MRI, with disease
duration of median 116 months (range 108–132).
They were suspected for MS and treated with
interferon-b previously, relapses occurred and treat-
ment was discontinued. One patient was diagnosed
with NMOSD 2 years before an attack with LME
on MRI. She was treated with azathioprine. For all
patients, median follow-up after onset of attack and
LME on MRI was 79.6 months (range 2–186).
DISCUSSION In this retrospective case series com-
prising 11 patients with AQP4-IgG–positive
NMOSD, we observed contrast enhancement of
the leptomeningeal structures during clinical attacks
accompanied by intraparenchymal contrast
enhancement spatially corresponding to the LME.
LME was observed in association with either an initial
area postrema attack, with precedent signs of systemic
infection or with detectable AQP4-IgG in CSF,
Figure 2 LETM in association with leptomeningeal enhancement
Sagittal (A.a and B.a) and axial (A.c and B.c) T1W contrast-enhanced images and sagittal T2W (A.b and B.b) and axial images
(A.d and B.d) of spinal cord MRI from 2 (A and B) AQP4-IgG–positive patients with NMOSD. Images were obtained during
acute LETM attacks with leptomeningeal and intraparenchymal (A.a and A.c at th10; B.a and B.c at th12) T1W contrast
enhancement. The spinal cord lesions were also demonstrated on T2W and STIR images (A.b, A.d, B.b, and B.d). AQP4-IgG5
aquaporin-4 immunoglobulin G; LETM 5 longitudinally extensive transverse myelitis; NMOSD 5 neuromyelitis optica
spectrum disorder; STIR 5 short tau inversion recovery; T1W 5 T1 weighted; T2W 5 T2 weighted.
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followed by secondary worsening of symptoms/signs
and lesions on MRI (figure e-2). These findings
suggest that, in some cases, entry of serum-derived
AQP4-IgG to the subarachnoid space may be facili-
tated by primary inflammation at area postrema
by systemic infection or by blood-CSF barrier
dysfunction (figure e-2). It could be speculated that
AQP4-IgG may be deposited at the astrocytic foot
processes at pial vessels and cause astrocytic damage.
The resultant dysfunction of AQP4 water channels in
the pial and subpial surfaces could lead to impairment
of leptomeningeal vessel barrier, which may be
involved in the development of NMOSD lesions.
In line with this study, pronounced meningeal
inflammation has been reported in autopsy findings
of patients with NMOSD.16 Our recent experimental
study of intrathecal injection of AQP4-IgG may cor-
roborate these findings, as pronounced deposition of
AQP4-IgG was observed in the leptomeningeal area,
including where pial vessels penetrate the brain paren-
chyma and form perivascular spaces into the brain
parenchyma,17 the so-called paravascular pathway.18
Furthermore, AQP4-IgG initiated perivascular
astrocyte-destructive lesions and consequently break-
down of the BBB.17 A significant proportion of sub-
arachnoid CSF circulates through the parenchyma
within these paravascular spaces19 which surround
penetrating and cerebral surface vessels20–22 and is
completely ensheathed by astrocyte end-feet.22 Of
interest, experimental data have suggested that the
flow of fluid along this paravascular route is mediated
by astrocytic AQP4.19
Although direct inferences from an animal study
are not possible, our observations suggest that intra-
parenchymal contrast enhancement lesions may form
in anatomical proximity to regions where LME is vis-
ible. LME was spatially associated with periependy-
mal enhancement and with intraparenchymal
enhancement in the brain, brainstem, hypothalamus,
optic chiasm, and spinal cord. These CNS MRI
abnormalities in patients with AQP4-IgG–positive
NMOSD are believed to be common and typical of
the disease with regards to localization and configu-
ration.2,23 Conversely, LME has been reported in few
patients only and is presumably more common dur-
ing NMOSD relapses and in AQP4-IgG–positive
patients.23,24 However, the frequency of LME is
likely to be underestimated given that most MRIs are
performed subsequently at onset of clinical symptoms
and thus at a time point where lesion formation is
probably completed and LME may have vanished.
Timing of MRI may be important for the demon-
stration of LME, and evaluation of MRI should
consider the interval between symptom onset and
MRI scan. Last, LME may be suppressed by steroid
treatment as immunosuppressive therapy probably
decreases BBB permeability.25 It has previously been
reported that corticosteroid treatment before MRI
may lead to the improvement or resolution of LME9
as part of the treatment response. In this study, pa-
tients received treatment with IV corticosteroid
before follow-up MRI, and this may have led to the
Figure 3 An area postrema lesion in association with leptomeningeal
enhancement and intraparenchymal BBB breakdown
Spinal cord MRI (A–C) and brain MRI (D–G) from an AQP4-IgG–positive patient with NMOSD
who presented with recurrent myelopathy of 1 month duration and area postrema lesion,
which progressed into LETM. Images were obtained during acute attacks. An area postrema
lesion (A) in association with subacute progression to LETM with leptomeningeal and intra-
parenchymal T1W contrast enhancement (arrows, B). The spinal cord lesions were also
demonstrated on T2W and STIR images (C). Cerebral MRI during another attack with peri-
ependymal enhancement on T1W images at the lateral (D) and third ventricles (F). FLAIR
images showing lesions along lateral ventricle (E), thalamus, and hypothalamus (G). (B) Used
with permission of the publisher from Flanagan EP, Weinshenker BG. Neuromyelitis optica
spectrum disorders. Curr Neurol Neurosci Rep 2014;14:483. Copyright © 2014, Springer
Science1Business Media New York. AQP4-IgG 5 aquaporin-4 immunoglobulin G; BBB 5
blood-brain barrier; FLAIR 5 fluid-attenuated inversion recovery; LETM 5 longitudinally
extensive transverse myelitis; NMOSD5 neuromyelitis optica spectrum disorder; T1W5 T1
weighted; T2W 5 T2 weighted.
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resolution of LME. The temporal evolution of alter-
ations to the BBB permeability is difficult to deter-
mine and will require a kinetic study with sequential
and frequent MRI images that analyze the dynamic
changes of enhancement in newly appearing active
lesions. The localization of the LME at the spinal cord
in 70% of cases was associated with extremely long
acute LETM lesions, and the patients were resistant
to steroid therapy. This may on MRI reflect the sever-
ity of attacks in the spinal cord at the time of LME.
However, such determination of an association
between the leptomeningeal blood-barrier disruption
and BBB breakdown sites and severity of attacks
require larger and prospective studies.
In this study, all cases were associated with disease
activity at the time of LME on MRI, and LME was
accompanied by other characteristic findings such as
LETM, area postrema lesion etc.11 In 7 of the 11
patients, the attacks occurred subacutely with
a dynamic progression of symptoms/signs. Four of
the seven patients had an initial area postrema syn-
drome. The dynamic formation of an LETM was
previously reported with initial involvement of the
area postrema during 12 days from the onset of symp-
toms as visualized on sequential brainstem/spinal
cord MRI.26 These findings support the concept that
area postrema, a circumventricular area which has
incomplete BBB, may serve as entry route to the
CNS for circulating AQP4-IgG.20,26,27
In NMOSD, the presence of AQP4-IgG in CSF
has been reported to be associated with high titers
of AQP4-IgG in serum,28–30 and to be strongly cor-
related with astrocyte damage, as reflected in elevated
levels of glial fibrillary acidic protein in the CSF and
BBB disruption during disease attacks.30,31 In this
small retrospective study, titers of AQP4-IgG in
serum were not determined and AQP4-IgG in CSF
was only measured in 2 patients, both of whom had
positive results.
Infections may result in events that alter the BBB
and thus permit access of AQP4-IgG to the CNS.32,33
Three cases with LETM were preceded acutely by
symptoms suggestive of systemic infection. Cases of
infectious or parainfectious events before the onset of
neurologic symptoms and NMOSD have been re-
ported, adding to the etiological diversity in
NMOSD.32–36 It is possible that infection may act
as a precipitating factor in the development of
NMOSD with the presence of AQP4-IgG.
We observed that leptomeningeal blood-barrier
integrity was compromised during relapses and was
accompanied by intraparenchymal BBB breakdown
in patients with AQP4-IgG–positive NMOSD.
Although our data are too preliminary to allow for
a firm statement on the putative mechanism of lesion
formation in human NMOSD, they suggest in con-
junction with previous animal experiments that the
question of how pathogenic AQP4-IgG gains access
to its CNS target deserves further attention. More-
over, future imaging studies may inform us about the
relevance of LME for attack severity and clinical
course in NMOSD.
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